Systems Pharmacology Modeling of Prostate‐Specific Antigen in Patients With Prostate Cancer Treated With an Androgen Receptor Antagonist and Down‐Regulator

First‐in‐human (FIH) studies with AZD3514, a selective androgen receptor (AR) down‐regulator, showed decreases of >30% in the prostate‐specific antigen (PSA) in some patients. A modeling approach was adopted to understand these observations and define the optimum clinical use hypothesis for AZD35...

Descripción completa

Detalles Bibliográficos
Autores principales: Mistry, HB, Fabre, M‐A, Young, J, Clack, G, Dickinson, PA
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879474/
https://www.ncbi.nlm.nih.gov/pubmed/27299938
http://dx.doi.org/10.1002/psp4.12066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879474/
https://www.ncbi.nlm.nih.gov/pubmed/27299938
http://dx.doi.org/10.1002/psp4.12066

Ejemplares similares